The identification of insulin signaling, growth hormone pathways, and longevity regulation links miR‐22 to systemic endocrine and metabolic control relevant to both primary and secondary sarcopenia (Fujita et al. 2006; Bian et al. 2020). This evidence concerns the gene INS and sarcopenia.